Quarterly report [Sections 13 or 15(d)]

Note 7 - Stockholder's Equity (Details Textual)

v3.25.1
Note 7 - Stockholder's Equity (Details Textual)
 3 Months Ended 26 Months Ended
Jun. 24, 2024
shares
May 10, 2024
USD ($)
$ / shares
Feb. 03, 2023
USD ($)
Mar. 31, 2025
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
Mar. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
$ / shares
shares
Jan. 05, 2024
USD ($)
$ / shares
shares
Nov. 30, 2023
$ / shares
shares
Jan. 31, 2023
$ / shares
shares
Jan. 30, 2023
shares
Sep. 22, 2022
Dec. 31, 2021
shares
Sep. 13, 2019
$ / shares
Sep. 13, 2016
shares
Preferred Stock, Shares Authorized (in shares)       2,000,000   2,000,000 2,000,000               2,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares       $ 0.0001   $ 0.0001 $ 0.0001                
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares   $ 0.0001   $ 0.0001   0.0001 0.0001                
Proceeds from Issuance of Common Stock | $       $ 2,094,000 $ 0                    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares       $ 8.64   $ 8.64 $ 8.64                
Class of Warrant or Right, Outstanding (in shares)       1,476,200   1,476,200 1,476,200                
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)       284                      
Invagen Pharmaceuticals Inc [Member]                              
Contingent Fee, Percentage of Proceeds of Future Financings     7.50%                        
Contingent Fee, Maximum Allowable Amount | $     $ 4,000,000                        
Payment of Contingent Fee | $       $ 200,000   $ 1,400,000                  
Restricted Stock Units (RSUs) [Member]                              
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $       $ 200,000   $ 200,000                  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       1 year 1 month 6 days                      
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)       45                      
Deferred Restricted Stock Units [Member]                              
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares)       235,000   235,000                  
Share-Based Payment Arrangement, Option [Member]                              
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $       $ 500,000   $ 500,000                  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)       1 year 2 months 12 days                      
Two Thousand Fifteen Incentive Plan [Member]                              
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) 5,070,223                       3,556    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)       4,575,701   4,575,701                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) 10 years                            
Two Thousand Fifteen Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options [Member]                              
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) 5,000,000                            
Two Thousand Fifteen Incentive Plan [Member] | Maximum [Member] | Share-Based Payment Arrangement, Nonemployee [Member]                              
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)                     70,223        
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) 500,000                            
January 2023 Warrants [Member]                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                   25,871          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares               $ 22.545   $ 116.25          
November 2023 Warrants [Member]                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                 194,667            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares               $ 22.545 $ 22.545            
New Series A Warrants [Member]                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)               220,538              
Warrants and Rights Outstanding, Term (Year)               5 years              
Warrants and Rights Issued Classified as Deemed Dividend | $               $ 600,000              
New Series B Warrants [Member]                              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)               220,538              
Warrants and Rights Issued Classified as Deemed Dividend | $               $ 4,300,000              
January 2024 Warrants [Member]                              
Class of Warrant or Right, Outstanding (in shares)       0   0                  
ATM Agreement [Member]                              
Offering Agreement, Maximum Amount | $   $ 3,850,000                          
Commission Fee, Percent Fee   3.00%                          
Stock Issued During Period, Shares, New Issues (in shares)       938,990                      
Proceeds from Issuance of Common Stock | $       $ 2,100,000                      
Preferred Class A [Member]                              
Preferred Stock, Shares Authorized (in shares)                             250,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares                           $ 0.0001  
Preferred Stock, Convertible, Conversion Ratio                       1,125